In CML, treatment with different TKIs led to an increased amount of NK cells in the bone marrow, whereas dasatinib was the only TKI with potent effect on CD8+ cytotoxic T cells [208]. Here, CD8A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.